PD173074

For research use only. Not for use in humans.

Pfizer辉瑞授权 目录号:S1264

PD173074 Chemical Structure

CAS No. 219580-11-7

PD173074 是一种有效的FGFR1抑制剂,在无细胞试验中IC50约为25 nM,也能抑制VEGFR2,IC50为100-200 nM,作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。PD173074 可在胃癌细胞中抑制增殖并促进凋亡。

规格 价格 库存 购买数量  
RMB 575.36 现货
RMB 985.04 现货
RMB 3867.14 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的PD173074发表文献81篇:

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述 PD173074 是一种有效的FGFR1抑制剂,在无细胞试验中IC50约为25 nM,也能抑制VEGFR2,IC50为100-200 nM,作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。PD173074 可在胃癌细胞中抑制增殖并促进凋亡。
靶点
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
体外研究

PD173074是FGFR1的ATP竞争性抑制剂, Ki约为40 nM。PD173074也是VEGFR2的有效抑制剂。相比FGFR1,PD173074弱抑制Src,INSR,EGFR,PDGFR,MEK和PKC的活性,IC 50值大1000倍以上。PD173074剂量依赖性地抑制FGFR1和VEGFR2的自身磷酸化,IC50 分别为1-5 nM和100-200 nM。[1] PD173074以剂量依赖的方式抑制FGF-2促进的颗粒神经元存活,IC50是12 nM,活性是SU 5402的1,000倍以上。[2] D173074特异性地抑制FGF-2-介导的少突胶质细胞(OL)谱系细胞的细胞增殖,分化和MAPK激活。[3] 在多发性骨髓瘤(MM)细胞系中,PD173074对野生受体和FGFR3突变有活性。PD173074还以剂量依赖的方式有效地抑制FGFR3的自磷酸化,IC50约为5 nM。PD173074有力地降低了表达FGFR3的KMS11细胞和KMS18细胞的活力,IC50小于20 nM。aFGF刺激的MM细胞生长受PD173074抑制是和FGFR3的表达高度相关的。PD173074完全抑制由Y373C FGFR3介导而不是的Ras介导的NIH 3T3转化,这表明PD173074专门针对FGFR3基因介导的细胞转化和缺乏非特异性的细胞毒性作用。PD173074也诱导KMS11和KMS18细胞功能成熟。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\tdHFSUUN3ME2wMlAyOjJ3IN88US=> NFTwSplUSU6JRWK=
KG-1 M2TDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\xcWlEPTB;MD6wOVEzQSEQvF2= NIjOOGZUSU6JRWK=
MFM-223 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nWZmlEPTB;MD6yNVU4PiEQvF2= NXS1eZFzW0GQR1XS
EoL-1-cell NUHFXIJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7HNpdKSzVyPUCuN|I6QDRizszN MYTTRW5ITVJ?
ECC10 NWXwR5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj5emF{UUN3ME2wMlM{QDl6IN88US=> NUTyRVVzW0GQR1XS
H-EMC-SS M2DCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jkRWlEPTB;MD6zOFcyPSEQvF2= NGn6eWdUSU6JRWK=
AN3-CA Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP1VGhKSzVyPUCuOFAyOzNizszN M2LjPHNCVkeHUh?=
HuO-3N1 NEfaOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNUS2OVMh|ryP NILsdHpUSU6JRWK=
RT-112 NEHYOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonoTWM2OD1yLkW0O|AyKM7:TR?= MWnTRW5ITVJ?
NEC8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNU[yPFkh|ryP NX60cYI2W0GQR1XS
D-263MG NV7xXIZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWwTWM2OD1yLkexNVU6KM7:TR?= NF;HdnZUSU6JRWK=
SW962 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwN{i5PFgh|ryP NX3vWIw6W0GQR1XS
BV-173 NGjYWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISwWoZKSzVyPUCuPFQ3OjNizszN NEXEfG9USU6JRWK=
MFE-280 M17NdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHXS2RGUUN3ME2wMlg2QDd{IN88US=> MojaV2FPT0WU
HuH-7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXQcoNCUUN3ME2xMlI1PDZ2IN88US=> NFW4W25USU6JRWK=
RS4-11 M{XWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu4TWM2OD1zLkOzPFg3KM7:TR?= MWrTRW5ITVJ?
DMS-114 NVHwTnppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPHUYVnUUN3ME2xMlM3PzN5IN88US=> MoTDV2FPT0WU
MSTO-211H M2C2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nBNWlEPTB;MT60O|M4QCEQvF2= NI\UbIlUSU6JRWK=
DU-145 NVfWc5dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwNUiyNVch|ryP NUP4U5F{W0GQR1XS
A172 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfvTWM2OD1zLkewN|U2KM7:TR?= Mk\SV2FPT0WU
SBC-1 M{HZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELSSJNKSzVyPUKuNFk1KM7:TR?= MWXTRW5ITVJ?
H9 NEWxZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjQTWM2OD1{LkG0N|A3KM7:TR?= NUfIcZB5W0GQR1XS
NCI-SNU-1 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHZOZRKSzVyPUKuNVg{QTRizszN MUDTRW5ITVJ?
NCI-H720 NH3H[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwMkGyPFMh|ryP MWfTRW5ITVJ?
HCC2218 NWXXUWdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe3PYtKSzVyPUKuN|c6OzlizszN M2\nUnNCVkeHUh?=
G-401 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTEbWRKUUN3ME2yMlQ4OTh7IN88US=> M2XaVXNCVkeHUh?=
MPP-89 NX;5eHd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwNEizOlQh|ryP NVfjVGR{W0GQR1XS
697 NGf5OnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFThNJFKSzVyPUKuOlU{OzFizszN M3zLdHNCVkeHUh?=
KARPAS-45 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwN{C3OFch|ryP NWfrN2ZoW0GQR1XS
MG-63 NF3Ne3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwOUSyOlIh|ryP NFe4OGJUSU6JRWK=
NTERA-S-cl-D1 NV\yXGVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwMEO0O|Ih|ryP NFfVfZlUSU6JRWK=
G-402 NFLt[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[4TWM2OD1|LkGyO|I4KM7:TR?= M1;NdXNCVkeHUh?=
NKM-1 NYnSW2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLEXnZNUUN3ME2zMlE{PTZ2IN88US=> NYjofZVSW0GQR1XS
RH-18 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwMUm1PVgh|ryP NFnPbXRUSU6JRWK=
NCI-H1092 M{D3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nYeWlEPTB;Mz6xPVY6KM7:TR?= NX;2bpBkW0GQR1XS
RPMI-8226 NVLFRZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULnU4psUUN3ME2zMlI{PDR5IN88US=> MX\TRW5ITVJ?
GAMG NFO5THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPYU|BKSzVyPUOuOFY2PzZizszN MYfTRW5ITVJ?
HH M1TjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHBbpBTUUN3ME2zMlQ4Pjd4IN88US=> MV;TRW5ITVJ?
RO82-W-1 NYDFRXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\NeFhKSzVyPUOuOFk5PTVizszN MXPTRW5ITVJ?
CCRF-CEM MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL3V3hTUUN3ME2zMlUxPDh6IN88US=> MUjTRW5ITVJ?
NBsusSR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHoUm0xUUN3ME2zMlY{QTZ7IN88US=> NGG4eHNUSU6JRWK=
CHL-1 NWXYSoVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7YWGJKUUN3ME2zMlY2Pzl7IN88US=> MkDRV2FPT0WU
LK-2 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjLTWM2OD1|Lk[3NVM{KM7:TR?= NHv5N2VUSU6JRWK=
Hs-578-T MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DnNmlEPTB;Mz62O|g4OyEQvF2= NITHXGxUSU6JRWK=
CTB-1 M3nMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfl[5VSUUN3ME2zMlgxODVzIN88US=> MYfTRW5ITVJ?
ES5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNwOEO2N|ch|ryP NXPzcI1TW0GQR1XS
A204 NVTkR4R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDWSVdsUUN3ME2zMlkzODd3IN88US=> M2rDNnNCVkeHUh?=
SW780 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDae2d2UUN3ME2zMlkzOjR3IN88US=> MmLJV2FPT0WU
EW-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;VNoVKSzVyPUOuPVg6OjNizszN NHHYVHBUSU6JRWK=
A704 NXzRVmNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPoeHZKSzVyPUSuNlg4OjNizszN MmPHV2FPT0WU
LU-139 M2GxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;xPY5KSzVyPUSuN|E2OzRizszN MnzGV2FPT0WU
CAL-72 M2rmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[w[2NKSzVyPUSuOFE4PDZizszN NHO5cVJUSU6JRWK=
D-336MG MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XZcGlEPTB;ND60OlgyPyEQvF2= NILPO5ZUSU6JRWK=
LAMA-84 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRwNUOzNUDPxE1? NGLOdoRUSU6JRWK=
GI-ME-N NFTUenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTHTWM2OD12LkW0PFEh|ryP NFrDZlBUSU6JRWK=
KM-H2 M3PldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;rPHYyUUN3ME20MlU2OjJ{IN88US=> MVPTRW5ITVJ?
NCI-H209 NF7qdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HQO2lEPTB;ND61PFI5OyEQvF2= NF2yVphUSU6JRWK=
IGROV-1 NYTiSXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fUeWlEPTB;ND64O|E3QCEQvF2= NEHqcWlUSU6JRWK=
L-363 NEXtd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjwTWM2OD12Lkm2OlY2KM7:TR?= NH34fm1USU6JRWK=
SK-MEL-3 M3[2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDqVXNKSzVyPUWuNlQxPiEQvF2= NVnDTpd2W0GQR1XS
HuO9 M1jQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjUTWM2OD13LkO4PFQ{KM7:TR?= NGfad5FUSU6JRWK=
NOS-1 NH;5cVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXa[HdTUUN3ME21MlczQTJ5IN88US=> Mlq5V2FPT0WU
NCI-H1770 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPwXJBQUUN3ME21Mlk2ODN{IN88US=> M1\TR3NCVkeHUh?=
SF126 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DiTmlEPTB;Nj6yNVQxPiEQvF2= M4nWXHNCVkeHUh?=
ML-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D1emlEPTB;Nj6yOFk4PyEQvF2= M2LSXnNCVkeHUh?=
CHP-134 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5do9jUUN3ME22MlI2OTh{IN88US=> MoTEV2FPT0WU
NCI-H1355 NVe2[WpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrqdWh3UUN3ME22MlQyPzN|IN88US=> MWLTRW5ITVJ?
TE-12 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TzTGlEPTB;Nj63NlY4OSEQvF2= MmnRV2FPT0WU
A4-Fuk NV3POHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXRSlJGUUN3ME22Mlc{OTR{IN88US=> NWXDN4lpW0GQR1XS
MV-4-11 NYGzSmRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7iTWM2OD14Lke2OlI3KM7:TR?= M3HuU3NCVkeHUh?=
SK-UT-1 M{DhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LXNWlEPTB;Nj65NVc5PCEQvF2= M3jSfHNCVkeHUh?=
J-RT3-T3-5 M3L4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPGTWM2OD15LkC3O|Y1KM7:TR?= M3nYeHNCVkeHUh?=
ME-180 M1zEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlezTWM2OD15LkGwOFA1KM7:TR?= NWnpbpdOW0GQR1XS
SK-MEL-28 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojVTWM2OD15LkO3PFE6KM7:TR?= NFTiXWhUSU6JRWK=
HAL-01 NE\zVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvzTWM2OD15LkS4N|QyKM7:TR?= M2XmOXNCVkeHUh?=
ES8 M3yxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3RSlBKSzVyPUeuOlk3OjZizszN NF;C[ndUSU6JRWK=
DB M2W3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TaTGlEPTB;OD6xNVUxPCEQvF2= MkXqV2FPT0WU
SK-NEP-1 NYC2bVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRThwNEixOFkh|ryP MoPiV2FPT0WU
COR-L88 M1vJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\kV2lEPTB;OD61NFk5OSEQvF2= NVXI[|Q{W0GQR1XS
LB1047-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml63TWM2OD16LkWyNlEzKM7:TR?= NVy0Zmp1W0GQR1XS
NCI-H520 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP4c|M4UUN3ME24MlYzOTV5IN88US=> MoDLV2FPT0WU
SW954 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7OXIF6UUN3ME24MlY6Pzh4IN88US=> M{DsXnNCVkeHUh?=
TE-6 NYTtS5czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n1fmlEPTB;OD63OVE1OyEQvF2= M4[xOHNCVkeHUh?=
D-283MED M1rHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTMTWM2OD17LkC2OVM1KM7:TR?= M4ryc3NCVkeHUh?=
DBTRG-05MG NYnvPXlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTlwMEm2NFch|ryP NVfjNm1PW0GQR1XS
NCI-H446 NV:0eIJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fvT2lEPTB;OT6yPVUzPiEQvF2= MkDTV2FPT0WU
HOS NFi5WpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW5ZpVKSzVyPUmuN|UyOzRizszN NWfp[|JpW0GQR1XS
ES4 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PJTmlEPTB;OT61NFU6PSEQvF2= M1[x[3NCVkeHUh?=
EW-13 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT4R21KSzVyPUmuPFkxPTVizszN MYjTRW5ITVJ?
IST-MES1 M3jwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3UTWM2OD17Lkm0OVM1KM7:TR?= MUHTRW5ITVJ?
CAS-1 NX6yc5ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHRdoZKSzVyPUmuPVc3PTlizszN M4TqOHNCVkeHUh?=
EM-2 M3nDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjIVIhKSzVyPUGwMlE{QTNizszN MV;TRW5ITVJ?
SW948 NHfxWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXPbGNGUUN3ME2xNE4yQDh{IN88US=> M{O5cnNCVkeHUh?=
OAW-42 NIrLR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W2VWlEPTB;MUCuOVI3PyEQvF2= MVPTRW5ITVJ?
BE-13 M3;Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L4VmlEPTB;MUCuOlU4PiEQvF2= NVv0UZlGW0GQR1XS
KU812 M1W2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO5ZZRbUUN3ME2xNE44OzlzIN88US=> NHTNbWhUSU6JRWK=
SK-MEL-30 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFyLki5NFEh|ryP M2TJT3NCVkeHUh?=
A2780 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLmOoY2UUN3ME2xNU4xOzB6IN88US=> NUTSdIlLW0GQR1XS
TGBC24TKB MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHKcHZKSzVyPUGxMlA4OzdizszN MYDTRW5ITVJ?
GOTO M4G1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPVVIRKSzVyPUGxMlIxQDRizszN MXfTRW5ITVJ?
NCI-H526 NF;QUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFzLkO4N|ch|ryP MkCxV2FPT0WU
BHT-101 NGXKeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG3NGdKSzVyPUGxMlQ1PTZizszN Mnu2V2FPT0WU
NCI-H1155 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonVTWM2OD1zMT60PVQ4KM7:TR?= MYXTRW5ITVJ?
MCF7 NHXTVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFzLk[xOlch|ryP M{LBZnNCVkeHUh?=
MKN45 NFPVT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq0TWM2OD1zMT63PVk{KM7:TR?= MWrTRW5ITVJ?
MOLT-16 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PLPWlEPTB;MUGuPVY6OiEQvF2= NYL2UZlKW0GQR1XS
YH-13 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjtRlNKSzVyPUGyMlA{PDZizszN M{TmPHNCVkeHUh?=
P12-ICHIKAWA NGG1bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHyTpN6UUN3ME2xNk4{QDR3IN88US=> MWrTRW5ITVJ?
GR-ST M4XGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzU[nB6UUN3ME2xNk42Ojl3IN88US=> NWDsPGdHW0GQR1XS
CAKI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoCwTWM2OD1zMj63PVEh|ryP M{\aXXNCVkeHUh?=
LXF-289 NEHteVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGwTWM2OD1zMz6wPFM2KM7:TR?= MkixV2FPT0WU
MHH-PREB-1 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJcmxqUUN3ME2xN{4zPzB2IN88US=> M37iPXNCVkeHUh?=
EW-16 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTxTWM2OD1zMz6zNVg4KM7:TR?= M3XUV3NCVkeHUh?=
NCI-H82 NUTrdHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF|LkSxPVUh|ryP Mlm1V2FPT0WU
MMAC-SF NHO0VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjWN21KSzVyPUGzMlQ2PDdizszN MV3TRW5ITVJ?
COLO-684 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PTXGlEPTB;MUOuOVMyQCEQvF2= NHv4fWNUSU6JRWK=
QIMR-WIL NXPTVGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF|LkixNFkh|ryP NXfEZXg2W0GQR1XS
NB69 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHQSnY1UUN3ME2xN{46QDZ6IN88US=> NXzQbXp2W0GQR1XS
NCI-H2291 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF2LkS0OVMh|ryP MlHXV2FPT0WU
MKN7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzGOJFKSzVyPUG0MlY3PzZizszN M1\HcHNCVkeHUh?=
HDLM-2 M{PzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTrNlgzUUN3ME2xOU4yOjh4IN88US=> MX7TRW5ITVJ?
A253 M1TrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLjTWM2OD1zNT6zPFY6KM7:TR?= MV3TRW5ITVJ?
SK-LU-1 M3X5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm1T2RvUUN3ME2xOU46ODl2IN88US=> M1y2[3NCVkeHUh?=
MEG-01 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\TcFZKSzVyPUG1MlkyODdizszN M4HXdnNCVkeHUh?=
SK-N-DZ MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XPTmlEPTB;MUWuPVM4PiEQvF2= Mn3tV2FPT0WU
H4 M1W3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ORZJuUUN3ME2xOk4xQDhizszN MWTTRW5ITVJ?
LU-65 M1HnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\VemJKSzVyPUG2MlM{QDRizszN MXrTRW5ITVJ?
NCI-H1048 Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDleHdKSzVyPUG2MlUyPjVizszN NXnM[XZZW0GQR1XS
LCLC-97TM1 NGrpTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHCb2xKSzVyPUG2MlU5QDlizszN NWHGd5ZNW0GQR1XS
CAL-120 M2rk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGwRpRKSzVyPUG2Mlk5PzlizszN MU\TRW5ITVJ?
LU-134-A NF76ZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF5LkOzPVEh|ryP NYXRUo5RW0GQR1XS
SK-MEL-1 NFraNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjkRpZKSzVyPUG3MlcyOjdizszN NXT1ZYhUW0GQR1XS
NCI-H69 NEjyWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT4dmN7UUN3ME2xO{46OzB5IN88US=> M370OXNCVkeHUh?=
MC116 NVm1Z5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\4cVRvUUN3ME2xO{46PzVizszN NFXVUGxUSU6JRWK=
UMC-11 M3j6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXyTWM2OD1zOD6xO|g5KM7:TR?= NVnFN2toW0GQR1XS
HCC1395 M{nvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF6LkSzNFEh|ryP NFf3TpdUSU6JRWK=
no-10 NX\QPGpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW5SnhxUUN3ME2xPE43Ozh6IN88US=> MlW0V2FPT0WU
NY NIXJd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPRTWM2OD1zOT6wPFA6KM7:TR?= NYDHdGR6W0GQR1XS
OS-RC-2 M4DXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fTe2lEPTB;MUmuNVI2OiEQvF2= NHz3c2VUSU6JRWK=
D-423MG MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\odXVKSzVyPUG5MlM6PTJizszN MlflV2FPT0WU
LC-2-ad NXrXbXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\6V2lEPTB;MUmuO|YyOiEQvF2= MnHiV2FPT0WU
DU-4475 NVnXbYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF7Lki4OVIh|ryP NFvGOZBUSU6JRWK=
YKG-1 NW[3Z2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF7Lkm2NkDPxE1? MnniV2FPT0WU
HCC1569 NGTSPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\uPZVKSzVyPUKwMlI3OjRizszN NYPBRol1W0GQR1XS
TYK-nu M4XxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTpTWM2OD1{MD6yPFQ4KM7:TR?= MnW5V2FPT0WU
DEL Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v4e2lEPTB;MkCuPVgxQCEQvF2= MoLxV2FPT0WU
MHH-ES-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJzLkO1PVch|ryP NIPUVplUSU6JRWK=
KARPAS-299 M4O0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz5VHZKSzVyPUKxMlUzQSEQvF2= NWm4OmRDW0GQR1XS
CTV-1 M1\3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvvcHR1UUN3ME2yNU43OTd{IN88US=> NFm0N2ZUSU6JRWK=
NCI-H2452 NXywdmh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW2TWM2OD1{Mj62Olc4KM7:TR?= M2T1OXNCVkeHUh?=
D-566MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L3WGlEPTB;MkKuO|YxOSEQvF2= Mk\5V2FPT0WU
EFO-27 M1XEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PoOmlEPTB;MkOuNFY2OSEQvF2= MV\TRW5ITVJ?
NCI-H596 M1PVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG3TWM2OD1{Mz64OVI4KM7:TR?= NXqyUplUW0GQR1XS
KS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXkTWM2OD1{ND6yO|U6KM7:TR?= MoXFV2FPT0WU
8305C NEXXWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rLVmlEPTB;MkSuOFA1PSEQvF2= MmHyV2FPT0WU
A427 NF25TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTXeGpKSzVyPUK1MlA{OjNizszN MYnTRW5ITVJ?
COLO-800 NVnST4R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzUTlhoUUN3ME2yOU4yODZzIN88US=> NGHQR5BUSU6JRWK=
SJRH30 NHvUcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TTe2lEPTB;MkWuN|kxQCEQvF2= NIS5fGlUSU6JRWK=
MEL-HO MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PxWGlEPTB;MkWuOFMyQSEQvF2= MXHTRW5ITVJ?
FTC-133 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml34TWM2OD1{NT64NVg3KM7:TR?= MXvTRW5ITVJ?
SF295 NX[xVno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\LZW05UUN3ME2yOk4zQTZizszN NGnx[41USU6JRWK=
SW1710 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL1ZWlKSzVyPUK2MlQyOjNizszN MYLTRW5ITVJ?
EFM-19 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PmemlEPTB;Mk[uPFE1PSEQvF2= MUnTRW5ITVJ?
NB10 NFTiOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrxVIZXUUN3ME2yPE4zOjl5IN88US=> M1\pb3NCVkeHUh?=
TK10 NHjGWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XS[mlEPTB;MkiuNlM6QSEQvF2= M4TLe3NCVkeHUh?=
D-502MG NF7OcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLISWJKSzVyPUK4MlQh|ryP MkTyV2FPT0WU
EW-18 NYn5cpA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ6LkSzPFYh|ryP MUDTRW5ITVJ?
VMRC-RCZ M13rUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfQTWM2OD1{OD65OFEh|ryP NIf5TIdUSU6JRWK=
Ca9-22 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz5eZFtUUN3ME2yPU41PTV5IN88US=> NHH0V4hUSU6JRWK=
KYSE-70 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTteIJrUUN3ME2yPU42Pzh4IN88US=> NX64O|E3W0GQR1XS
A101D MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ7Lk[0O|Ih|ryP M{jnWXNCVkeHUh?=
WM-115 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ7Lke2NFch|ryP NGfmSJVUSU6JRWK=
HCC2157 NGr5VWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\sNopyUUN3ME2yPU45QDB5IN88US=> MVPTRW5ITVJ?
TE-9 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPGTWM2OD1{OT64PFY2KM7:TR?= NHfNcGlUSU6JRWK=
K-562 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLjTWM2OD1|MD6wPVM{KM7:TR?= NG\ROGhUSU6JRWK=
SN12C M4jWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvQTWM2OD1|MD6xOFI3KM7:TR?= MoOzV2FPT0WU
ESS-1 M2LpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPpWlh3UUN3ME2zNE41PzV7IN88US=> NH34OodUSU6JRWK=
K5 NEnxbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNyLke2OEDPxE1? Mk\6V2FPT0WU
J82 NHjjN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XUUmlEPTB;M{GuNFg6PyEQvF2= NWnRZ4hEW0GQR1XS
HOP-92 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnEU4VWUUN3ME2zNU4yOTFzIN88US=> MlXqV2FPT0WU
NCI-H2228 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrETWM2OD1|MT6zNlk3KM7:TR?= NEH2T5NUSU6JRWK=
OCI-AML2 NVvhV|BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHmVW9KSzVyPUOxMlM3OSEQvF2= NF75dVBUSU6JRWK=
NCI-SNU-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn2UYRLUUN3ME2zNU45OTN5IN88US=> MYLTRW5ITVJ?
A3-KAW M4TwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS2RWNCUUN3ME2zNU46OjR|IN88US=> NWjpOldwW0GQR1XS
LCLC-103H MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnkRmhFUUN3ME2zNk4xOTdzIN88US=> MX7TRW5ITVJ?
KY821 NHPQOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN{Lk[4PFQh|ryP MVfTRW5ITVJ?
JVM-2 NUnWc5I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTSN2VKSzVyPUOyMlkxPzlizszN M3zsNXNCVkeHUh?=
Mo-T M4HONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5TWM2OD1|Mz6xNFA2KM7:TR?= M2fBTHNCVkeHUh?=
IA-LM M3TBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3nXmVKSzVyPUOzMlI4PSEQvF2= NYPxWmlHW0GQR1XS
C8166 NF2xVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TBZWlEPTB;M{OuN|E6OiEQvF2= M2\IO3NCVkeHUh?=
TCCSUP NV3veYVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDWTWM2OD1|Mz60N|A4KM7:TR?= Mm\RV2FPT0WU
JEG-3 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLVTWM2OD1|Mz60O|Y5KM7:TR?= M1XVWHNCVkeHUh?=
MS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFe|V6UUN3ME2zN{42PTVzIN88US=> NHG0NGhUSU6JRWK=
NCI-H1304 NYfze3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\wSWlEPTB;M{OuOVczPSEQvF2= NIPLNmxUSU6JRWK=
Ramos-2G6-4C10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LNVWlEPTB;M{SuNFM{PSEQvF2= NXXTWnN3W0GQR1XS
MDA-MB-453 NEjKd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDnUFNKSzVyPUO0MlY{QTVizszN NHL5UXJUSU6JRWK=
KYSE-520 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PpR2lEPTB;M{SuO|E5OSEQvF2= MYXTRW5ITVJ?
SW900 NGnteZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrVOGt[UUN3ME2zOE45OTF3IN88US=> NF36NotUSU6JRWK=
HCC2998 MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi1W5FKSzVyPUO1MlE2OjlizszN NY[2NVYyW0GQR1XS
A2058 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN3Lk[wOlEh|ryP M{LUPXNCVkeHUh?=
OVCAR-3 M4jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN4LkKwOFUh|ryP MnXXV2FPT0WU
MOLT-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN4LkKyPVQh|ryP MkTQV2FPT0WU
CAPAN-1 M2fVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rUbWlEPTB;M{[uOFY6QSEQvF2= MUTTRW5ITVJ?
SCC-9 M{LVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTN5LkSwNlch|ryP M4CwVXNCVkeHUh?=
SF268 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17nVWlEPTB;M{iuN|Q{OyEQvF2= NULaco8yW0GQR1XS
HGC-27 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN6LkO3NVEh|ryP NX;HT5N2W0GQR1XS
DOHH-2 NEXTeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmO0TWM2OD1|OD63NVU5KM7:TR?= NFL2T2JUSU6JRWK=
KE-37 M{jjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjqfFFZUUN3ME2zPE46QDJ6IN88US=> M1vMd3NCVkeHUh?=
MOLT-13 M1zkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTJdYFQUUN3ME2zPU4zPTB{IN88US=> MmL2V2FPT0WU
ES1 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y0TWlEPTB;M{muN|g2KM7:TR?= NGH6PZBUSU6JRWK=
SK-OV-3 NUHyPVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN7Lkm2OFMh|ryP NXzh[I1EW0GQR1XS
SNU-449 NF[wZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCTWM2OD12MD6wO|Y1KM7:TR?= MVfTRW5ITVJ?
KYSE-510 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK1OmZUUUN3ME20NE4yOjl3IN88US=> M1nFd3NCVkeHUh?=
HL-60 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPlTGhSUUN3ME20NE46Pzh|IN88US=> NH24cplUSU6JRWK=
DJM-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnaWW5KSzVyPUSwMlk4QTlizszN MYnTRW5ITVJ?
TGBC11TKB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXruUlhsUUN3ME20NU4xQTJ4IN88US=> NXr4c3VvW0GQR1XS
U-2-OS MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37JfGlEPTB;NEKuNlY1OSEQvF2= NE\0SWVUSU6JRWK=
NCI-H2030 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojvTWM2OD12Mj60N|Y5KM7:TR?= M{TMSXNCVkeHUh?=
LU-135 NXnhWG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LwRWlEPTB;NEKuOVQ1PyEQvF2= MojOV2FPT0WU
ZR-75-30 NWnoWm17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nrN2lEPTB;NEOuNFQ6OyEQvF2= M1y4b3NCVkeHUh?=
GT3TKB M4PoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;YTWM2OD12Mz6yOlc6KM7:TR?= NEHwbWtUSU6JRWK=
RPMI-2650 NHTwOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTR|Lke4NVYh|ryP NV\4TnAyW0GQR1XS
SAS M13j[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDvSpBGUUN3ME20N{46PTN2IN88US=> NFvybJlUSU6JRWK=
MDA-MB-231 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPMTWM2OD12Mz65OlA6KM7:TR?= NVfvWoJwW0GQR1XS
JVM-3 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn2eHc3UUN3ME20OE4xPTN|IN88US=> M37YTHNCVkeHUh?=
COLO-320-HSR NHPRZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTR2LkW2N|Mh|ryP MVrTRW5ITVJ?
SNB75 M{LTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LSWWlEPTB;NESuOlExPSEQvF2= NWnmUZdjW0GQR1XS
NCI-H441 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT0fIdKSzVyPUS0Mlk{OjhizszN MlHHV2FPT0WU
HCT-116 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjFTWM2OD12ND65PFY5KM7:TR?= MlXqV2FPT0WU
NCI-H226 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfqTWM2OD12NT62N|Y5KM7:TR?= NGGwTmpUSU6JRWK=
CAL-33 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS2TWM2OD12NT65NlE4KM7:TR?= MYfTRW5ITVJ?
NCI-H1437 M3PnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnIWXJKSzVyPUS2MlMzOSEQvF2= MUDTRW5ITVJ?
HCC1187 NYnybIx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHNS45KSzVyPUS2MlQzPTVizszN M3\ofnNCVkeHUh?=
NUGC-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR4LkW3NFkh|ryP NV;mXolKW0GQR1XS
T98G NH;HboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL4SmRHUUN3ME20O{42PDdizszN MV3TRW5ITVJ?
OVCAR-8 M1u4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH1WHpKSzVyPUS3MlY5OyEQvF2= NUe0SIlQW0GQR1XS
LB2241-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjyNphQUUN3ME20O{44OjdizszN MXzTRW5ITVJ?
NCI-H358 M17IRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGyXZFRUUN3ME20PE4yOTV{IN88US=> M{nDW3NCVkeHUh?=
PANC-08-13 NH3VWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfzRmNtUUN3ME20PE4yQDV|IN88US=> NFnzeXVUSU6JRWK=
KP-N-YN NYPNWmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TjdWlEPTB;NEiuNlExOiEQvF2= NVi2UIRyW0GQR1XS
NCI-H1755 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7oOmFDUUN3ME20PE4zPzJ4IN88US=> M2jt[nNCVkeHUh?=
NCI-N87 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSwRWpKSzVyPUS4MlI6QTFizszN Mmr3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFGFR2 / FGFR2 ; 

PubMed: 24968263     


PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody.

p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; 

PubMed: 24968263     


Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.

24968263
Growth inhibition assay
Cell viability; 

PubMed: 24968263     


B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism. 

24968263
体内研究 PD173074在1 mg/kg/day或2 mg/ka/day对小鼠给药可以剂量依赖性的方式有效阻止由FGF或VEGF诱导的血管生成,并没有明显的毒性。[1] PD173074抑制FGFR3突变体转染的NIH 3T3细胞在裸鼠体内生长。在KMS11异种移植瘤模型中,PD173074抑制FGFR3导致肿瘤生长延缓,小鼠的存活率提高。[4] 在H-510异种移植体中,PD173074阻断肿瘤生长和cisplatin相似,与对照假治疗的动物相比增加中位生存期。在H-69异种移植体中,PD173074在50%小鼠中的诱导作用长于6个月。这些效应是和切除肿瘤中增加的细胞凋亡相关的,而非破坏肿瘤血管。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外激酶抑制试验:

检测是使用全长FGFR-1激酶在100微升含25 mM HEPES缓冲液(pH7.4),150 mM氯化钠,10 mM MnCl2,0.2 mM的原钒酸钠,750 μg/mL谷氨酸和酪氨酸(4:1)的无规共聚物,各种浓度的PD173074,和60至75 ng酶中进行的。该反应通过加入[γ-32P]ATP(含有0.4 μCi of [γ-32P]ATP的5 μM ATP)起始,样品在25°C孵育10分钟。反应通过加入30%三氯乙酸和材料的沉淀到玻璃纤维滤垫上终止。过滤器用15%三氯乙酸洗涤三次,掺入[32P]到谷氨酸酪氨酸聚合物衬底是通过计算保留在过滤器上的放射性来确定,通过WALLAC1250 betaplate阅读器读取。非特异性的活性被定义为温育不含酶的样品保留在过滤器上放射性。特异活性被确定为总活性(酶加缓冲液)减去非特异性活性。PD173074抑制FGFR-1的酶活性的IC50浓度用图解法测定。
细胞实验:[4]
- 合并
  • Cell lines: KMS11和 KMS18
  • Concentrations: 溶解在DMSO中至终浓度~100 nM
  • Incubation Time: 48小时
  • Method: 在aFGF/肝素的存在下,细胞在PD173074浓度梯度中孵育48小时。活细胞的百分比由MTT法检测。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 诱导角膜新生血管的瑞士韦伯斯特小鼠
  • Dosages: 约2 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+corn oil
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 523.67
化学式

C28H41N7O3

CAS号 219580-11-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the half-life of PD173074(S1264) in vivo?

  • 回答:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品

Tags: 购买PD173074 | PD173074供应商 | 采购PD173074 | PD173074价格 | PD173074生产 | 订购PD173074 | PD173074代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID